Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: H05BX01

Cinacalcet Viatris (previously Cinacalcet Mylan)(cinacalcet hydrochloride)

Hyperparathyroidism, Secondary;Hypercalcemia

Marketing Authorisation Holder: Mylan Pharmaceuticals Limited

EMA Authorisation: 19/11/2015

INN: cinacalcet

Indication

Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Cinacalcet Mylan may be used as part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with: parathyroid carcinoma primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Cinacalcet Viatris (previously Cinacalcet Mylan) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.